Form 4: Nuvation Bio Director Robert Mashal Increases Stake in Company
SEC Form 4 Filing
Director Robert Mashal increases his stake in Nuvation Bio through trust purchases of Class A Common Stock.
Summary
- Robert Mashal, a director of Nuvation Bio Inc., has reported changes in beneficial ownership of the company's Class A Common Stock.
- On October 8, 2024, Mashal's trust acquired 19 shares at $2.195 per share and 99,981 shares at $2.2 per share.
- Following these transactions, the trust now holds 100,000 shares of Nuvation Bio Inc.
- The shares are owned directly by the Robert D. Mashal 2020 Revocable Trust, of which Robert Mashal is the sole trustee.
Sentiment
Score: 6
Explanation: The sentiment is neutral. It's a routine disclosure of insider trading activity. The director's increased stake could be interpreted positively, but without further context, it's difficult to gauge the overall impact.
Positives
- A director increasing their stake in the company could be seen as a positive signal to investors.
Industry Context
Form 4 filings are a routine part of insider trading regulations, providing transparency into the transactions of company insiders.
Stakeholder Impact
- Shareholders may view the director's increased stake as a sign of confidence in the company's future.
Key Dates
| Date | Description |
|---|---|
| 10/08/2024 | Date of transaction: Purchase of Class A Common Stock |
| 10/10/2024 | Date of signature on the Form 4 filing |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.